GO Main Menu Go Main Contents Go Bottom Menu
  • 94
    European Commission approves Celltrion Healthcare’..
    European Commission approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the treatment of multiple types of cancer · Vegzelma™ offers European patients living with certain types of breast, lung, renal, colon, rectum…
    2022-08-19
  • 93
    Celltrion Healthcare receives CHMP positive opinio..
    Celltrion Healthcare receives CHMP positive opinion for biosimilar bevacizumab, Vegzelma™ (CT-P16) • Vegzelma™ (CT-P16), a biosimilar candidate referencing Avastin®(bevacizumab)1, is Celltrion’s third oncology biosimilar…
    2022-06-27
  • 92
    New data show statistically greater improvements i..
    New data show statistically greater improvements in clinical outcomes with subcutaneous infliximab, compared to intravenous infliximab, in patients with rheumatoid arthritis - Presented today at EULAR 2022, data from a new post-hoc analysis s…
    2022-06-02
  • 91
    Celltrion Healthcare wins tender to supply Remsima..
    Celltrion Healthcare wins tender to supply Remsima® to the Brazilian Federal Government • Remsima® is the third biosimilar product for Celltrion Healthcare to win tender in Brazil following Truxima® and Herzuma® • The company will be supplying R…
    2022-03-24
  • 90
    Switching to subcutaneous infliximab leads to high..
    Switching to Subcutaneous Infliximab Leads to Higher Trough Level and Low Risk of Relapse in Patients with Inflammatory Bowel Disease - New data from the REMSWITCH study shows switching from intravenous (IV) to subcutaneous (SC) infliximab leads t…
    2022-03-02
  • 89
    Celltrion Submits IND Application to Initiate a Gl..
    Celltrion Submits Investigational New Drug (IND) Application to Initiate a Global Phase III Clinical Trial Evaluating an Inhaled COVID-19 Antibody Cocktail Therapy Celltrion submitted an IND application for a global Phase III clinical trial of …
    2022-02-07
  • 88
    Celltrion announces positive results for its cockt..
    Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant CT-P63 demonstrated a well- established safety profile in the global Phase I trial CT-P63 maintained str…
    2022-01-03
  • 87
    TGA grants provisional approval for Celltrion’s re..
    TGA grants provisional approval for Celltrion’s regdanvimab (regkirona) ·The monoclonal antibody treatment is provisionally approved for the intravenous treatment of mild-to-moderate COVID-19 patients in Australia[1] December 7, 2021,INCHEON, KO…
    2021-12-07
  • 86
    Celltrion accelerates development of nebulised coc..
    Celltrion accelerates development of nebulised cocktail therapy (CT-P63 in combination with CT-P59) using its antibody platform to tackle new COVID-19 variants Celltrion previously completed phase I clinical trials with a nebulised f…
    2021-11-29
  • 85
    Celltrion’s Monoclonal Antibody Treatment regdanvi..
    Celltrion’s Monoclonal Antibody Treatment regdanvimab, Approved by the European Commission for the Treatment of COVID-19 The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following positive…
    2021-11-15